Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct 25;55(20):8582-7.
doi: 10.1021/jm300612z. Epub 2012 Oct 16.

(S)-N-(2,5-Dimethylphenyl)-1-(quinoline-8-ylsulfonyl)pyrrolidine-2-carboxamide as a small molecule inhibitor probe for the study of respiratory syncytial virus infection

Blake P Moore  1 , Dong Hoon Chung, Daljit S Matharu, Jennifer E Golden, Clinton Maddox, Lynn Rasmussen, James W Noah, Melinda I Sosa, Subramaniam Ananthan, Nichole A Tower, E Lucile White, Fuli Jia, Thomas E Prisinzano, Jeffrey Aubé, Colleen B Jonsson, William E Severson
Affiliations

(S)-N-(2,5-Dimethylphenyl)-1-(quinoline-8-ylsulfonyl)pyrrolidine-2-carboxamide as a small molecule inhibitor probe for the study of respiratory syncytial virus infection

Blake P Moore et al. J Med Chem. .

Abstract

A high-throughput, cell-based screen was used to identify chemotypes as inhibitors for human respiratory syncytial virus (hRSV). Optimization of a sulfonylpyrrolidine scaffold resulted in compound 5o that inhibited a virus-induced cytopathic effect in the entry stage of infection (EC₅₀ = 2.3 ± 0.8 μM) with marginal cytotoxicity (CC₅₀ = 30.9 ± 1.1 μM) and reduced viral titer by 100-fold. Compared to ribavirin, sulfonylpyrrolidine 5o demonstrated an improved in vitro potency and selectivity index.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structure of ribavirin 1
Figure 2
Figure 2
Shaded regions of hit compound 2 optimized by structure-activity relationships.
Figure 3
Figure 3
Comparison of ribavirin with analogs 5b, 5o and 5t in a time of addition assay.
Scheme 1
Scheme 1. Chemical Synthesis of Sulfonylpyrrolidine Analogs
Reagents and conditions: (a) L-proline, 10% aq. K2CO3, THF, 50 °C, 5 h, then 3N HCl; (b) DIPEA, HATU, substituted aniline, DMF, rt, 2 h.
See this image and copyright information in PMC

References

    1. Greenough A. Respiratory syncytial virus infection: clinical features, management, and prophylaxis. Curr. Opin. Pulm. Med. 2002;8:214–217. - PubMed
    1. Langley GF, Anderson LJ. Epidemiology and Prevention of Respiratory Syncytial Virus Infections Among Infants and Young Children. Pediatr. Infect. Dis. J. 2011;30:510–517. - PubMed
    1. Englund JA, Piedra PA, Whimbey E. Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients. Am. J. Med. 1997;102:61–70. discussion 75–76. - PubMed
    1. Jeffcoate TN. Vaccine against respiratory syncytial virus. Lancet. 1969;7615:311. - PubMed
    1. Hemming VG. Respiratory syncytial virus: a brief history, in Contemporary diagnosis and management of respiratory syncytial virus. In: Weisman LE, Groothuis JR, editors. Handbooks in Health Care Co. Newtown, PA: 2000. pp. 7–23.

Publication types

MeSH terms